Treatment of Type II Endoleaks with a Novel Agent: Precipitating Hydrophobic Injectable Liquid (PHIL)

Helmy, Amir; Shaida, Nadeem

doi:10.1007/s00270-017-1603-7

Cited by 12 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the different NALEA for E2, Onyx is the most widely used followed by Squid. Recently, a case report describing a successful embolization of E2 using Phil has also been published [ 46 , 55 ] with similar results…”

Section: Endoleakmentioning

confidence: 67%

Non-Adhesive Liquid Embolic Agents in Extra-Cranial District: State of the Art and Review of the Literature

Piacentino

Fontana

Curti

et al. 2021

JCM

View full text Add to dashboard Cite

This review focuses on the use of “new” generation of non-adhesive liquid embolic agents (NALEA). In literature, non-adhesive liquid embolic agents have mainly been used in the cerebral district; however, multiple papers describing the use of NALEA in the extracranial district have been published recently and the aim of this review is to explore and analyze this field of application. There are a few NALEA liquids such as Onyx, Squid, and Phil currently available in the market, and they are used in the following applications: mainly arteriovenous malformations, endoleaks, visceral aneurysm or pseudoaneurysm, presurgical and hypervascular lesions embolization, and a niche of percutaneous approaches. These types of embolizing fluids can be used alone or in combination with other embolizing agents (such as coils or particles) so as to enhance its embolizing effect or improve its possible defects. The primary purpose of this paper is to evaluate the use of NALEAs, predominantly used alone, in elective embolization procedures. We did not attempt a meta-analysis due to the data heterogeneity, high number of case reports, and the lack of a consistent follow-up time period.

show abstract

Section: Endoleakmentioning

confidence: 67%

Non-Adhesive Liquid Embolic Agents in Extra-Cranial District: State of the Art and Review of the Literature

Piacentino

Fontana

Curti

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…First Easyx use in humans was recently reported by Sapoval et al ( 20 ) and includes results at 6 months follow-up for 7 endoleak procedures among 50 patients. Literature about Precipitating hydrophobic injectable liquid (PHIL; Micro-Vention, Tustin, California) use in T2E is limited to small case series with three patients ( 21 ). No randomized controlled trial comparing different liquid agents is available at the moment of submission.…”

Section: Discussionmentioning

confidence: 99%

Translumbar type II endoleak embolization with a new liquid iodinated polyvinyl alcohol polymer: Case series and review of current literature

et al. 2023

View full text Add to dashboard Cite

PurposeTo describe our experience with the use of a novel iodized Polyvinyl Alcohol Polymer liquid agent (Easyx) in type II endoleak treatment with translumbar approach.MethodsOur case series is a retrospective review of patients with type II endoleak (T2E) treated with Easyx from December 2017 to December 2020. Indication for treatment was a persistent T2E with an increasing aneurysm sac ≥5 mm on computed tomography angiography (CTA) over a 6-month interval. Technical success was defined as the embolization of the endoleak nidus with reduction or elimination of the T2E on sequent CTA evaluation. Clinical success was defined as an unchanged or decreased aneurysm sac on follow-up CTA. Secondary endpoints included the presence of artifacts in the postprocedural cross-sectional tomographic imaging and post and intraprocedural complications.ResultsTen patients were included in our retrospective analysis. All T2E were successfully embolized. Clinical success was achieved in 9 out of 10 patients (90%). The mean follow-up was 14 3–20 months. No beam hardening artifact was observed in follow-up CT providing unaltered imaging.ConclusionEasyx is a novel liquid embolic agent with lava-like characteristics and unaltered visibility on subsequent CT examinations. In our initial experience, Easyx showed to have all the efficacy requisites to be an embolization agent for type II EL management. Its efficacy, however, should be evaluated in more extensive studies and eventually compared with other agents.

show abstract

“…The precipitating hydrophobic injectable liquid PHIL s (Micro-Vention (Terumo Corp)) is indicated for the embolisation of the peripheral and neurovasculature, including AVMs and hypervascular tumours. [47][48][49] The liquid embolic is delivered using DMSO as the carrier solvent which on mixing with blood diffuses away as the polymeric material precipitates out of solution on contact with the aqueous environment within the vasculature to form a solid embolus. The polymer is based on a 2,4,6-triidophenol-lactide-lactide-co-glycolic acrylate and hydroxyethyl-methacrylate (HEMA) (2 : 1 monomer ratio) copolymer which is non-adhesive in nature so avoids adhesion to the microcatheter during delivery (Fig.…”

Section: Precipitating Hydrophobic Injectable Liquid (Phil S S )mentioning

confidence: 99%

Advancements in the development on new liquid embolic agents for use in therapeutic embolisation

et al. 2020

View full text Add to dashboard Cite

show abstract

Treatment of Type II Endoleaks with a Novel Agent: Precipitating Hydrophobic Injectable Liquid (PHIL)

Abstract: PHIL is a promising novel embolic agent in the treatment of type II endoleaks, our initial experience has been positive but larger series will be required to evaluate this further.

Cited by 12 publications

References 17 publications

Non-Adhesive Liquid Embolic Agents in Extra-Cranial District: State of the Art and Review of the Literature

Non-Adhesive Liquid Embolic Agents in Extra-Cranial District: State of the Art and Review of the Literature

Translumbar type II endoleak embolization with a new liquid iodinated polyvinyl alcohol polymer: Case series and review of current literature

Advancements in the development on new liquid embolic agents for use in therapeutic embolisation

Contact Info

Product

Resources

About